ARCHIVED: Appendix 7a: The Management of the National Antiviral Stockpile: Options Report - Purchase requirements, by jurisdiction, to meet paediatric oseltamivir, zanamivir, and amantadine targets

**APPENDIX 7a: Purchase requirements, by jurisdiction, to meet paediatric oseltamivir, zanamivir, and amantadine targets¹**
(costs for purchases, by jurisdiction, were provided to Public Health Network Council)
Jurisdiction²	Remaining doses³ paediatric oseltamivir to be purchased		Zanamivir paediatric doses	Zanamivir adult doses	Amantadine doses (additional 10% of NAS)
Notes: 1 2008 Population Estimates: Total population >1 year of age = 33 million; total paediatric population (1-<12) = 4 million; total adult population (12+) = 29 million ² P/T Proportions Used: 2008 total population census data ³ There are already approx. 2 million paediatric oseltamivir capsules already in the NAS and distributed to P/Ts on a per capita basis, the table reflects the remaining 7.2 million doses to be purchased. ⁴NT adult oseltamivir stock does not expire until 2011. Options to be discussed with PWGSC in order to meet paediatric targets through Exchange program, etc.
Jurisdiction²	30 mg capsules	45 mg capsules	Zanamivir paediatric doses	Zanamivir adult doses	Amantadine doses (additional 10% of NAS)
NAS	5,923,165	1,247,983	700,000	5,000,000	5,800,000
NL (1.5%)	87,439	20,414	10,673	76,234	88,432
PEI (.4%)	24,233	5,650	2,938	20,987	24,344
NS (2.8%)	162,247	37,979	19,717	140,839	163,373
NB (2.2%)	130,062	30,555	15,704	112,169	130,116
QC (23.3%)	1,348,612	316,832	162,868	1,163,341	1,349,476
ON (38.8%)	2,374,679	414,366	271,688	1,940,627	2,251,127
MB (3.6%)	210,417	49,418	25,384	181,313	210,323
SK (3%)	160,920	36,240	21,350	152,498	176,898
AB (10.8%)	637,638	151,279	75,338	538,126	624,226
BC (13.2%)	768,006	180,894	92,074	657,673	762,901
YK (.1%)	5,885	1,361	696	4,975	5,771
NT (.1%)	7,514⁴	1,730⁴	910	6,497	7,536
NU (.1%)	5,512	1,266	661	4,720	5,476

Page details